Video

Dr. Ramnaraign on Current Treatment Guidelines for First-Line Metastatic RCC

Brian Ramnaraign, MD, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma. 

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Brian Ramnaraign, MD, assistant professor of medicine, Division of Hematology and Oncology, University of Florida College of Medicine, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma (RCC). 

    Currently, many first-line treatment options are available for use in this patient population, according to Ramnaraign. When choosing among these approaches, is important to determine whether a patient has favorable-, intermediate-, or poor-risk disease, Ramnaraign says. 

    There are 3 category 1 National Comprehensive Cancer Network recommendations for patients with favorable-risk disease, and 4 recommendations for those with intermediate- and poor-risk disease, Ramnaraign explains.

    For patients with poor- or immediate-risk disease, possible treatment strategies include dual immunotherapy regimens or immunotherapies in combination with TKIs. For those with favorable-risk disease, immunotherapy/TKI combinations are often utilized, Ramnaraign concludes.

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data